|
Bart S A,
Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer P R, Kanesa-Thasan N.
2014. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is
immunogenic in adults. Science Translational Medicine, 6,
234ra255.
Cao Y Z, Deng
J, Huang Y, Bo Z Y, Hu Z L. 2023. Generation and application of 293T cell line
stably expressing the haemugglutinin of H7N9 subtype avian influenza virus. China Poultry, 45, 59–64. (in Chinese)
Chang P,
Lukosaityte D, Sealy J E, Rijal P, Sadeyen J R, Bhat S, Crossley S, Daines R,
Huang K A, Townsend A R, Iqbal M. 2023a. Antigenic characterization of human
monoclonal antibodies for therapeutic use against H7N9 avian influenza virus. Journal of Virology, 97, e0143122.
Chang P,
Sadeyen J R, Bhat S, Daines R, Hussain A, Yilmaz H, Iqbal M. 2023b. Risk
assessment of the newly emerged H7N9 avian influenza viruses. Emerging Microbes Infections, 12, 2172965.
Coudeville L,
Bailleux F, Riche B, Megas F, Andre P, Ecochard R. 2010. Relationship between
haemagglutination-inhibiting antibody titres and clinical protection against
influenza: Development and application of a bayesian random-effects model. BMC Medical Research Methodology, 10, 18.
Dunand C J H,
Leon P E, Huang M, Choi A, Chromikova V, Ho I Y, Tan G S, Cruz J, Hirsh A,
Zheng N Y, Mullarkey C E, Ennis F A, Terajima M, Treanor J J, Topham D J,
Subbarao K, Palese P, Krammer F, Wilson P C. 2016. Both neutralizing and
non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies
confer protection. Cell Host Microbe, 19, 800–813.
Fox J M, Roy
V, Gunn B M, Huang L, Edeling M A, Mack M, Fremont D H, Doranz B J, Johnson S,
Alter G, Diamond M S. 2019. Optimal therapeutic activity of monoclonal
antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes. Science Immunology, 4, eaav5062.
Gao R B, Cao
B, Hu Y W, Feng Z J, Wang D Y, Hu W F, Chen J, Jie Z J, Qiu H B, Xu K, Xu X W,
Lu H Z, Zhu W F, Gao Z C, Xiang N J, Shen Y Z, He Z B, Gu Y, Zhang Z Y, Yang Y, et al. 2013. Human infection with a novel avian-origin influenza A
(H7N9) virus. New England Journal of Medicine, 368, 1888–1897.
Ge J Y, Deng
G H, Wen Z Y, Tian G B, Wang Y, Shi J Z, Wang X J, Li Y B, Hu S, Jiang Y P,
Yang C L, Yu K Z, Bu Z G, Chen H L. 2007. Newcastle disease virus-based live
attenuated vaccine completely protects chickens and mice from lethal challenge
of homologous and heterologous H5N1 avian influenza viruses. Journal of Virology, 81, 150–158.
Gunn B M, Yu
W H, Karim M M, Brannan J M, Herbert A S, Wec A Z, Halfmann P J, Fusco M L,
Schendel S L, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich T J, Lai
J, Chandran K, Zeitlin L, Crowe Jr J E, Lauffenburger D, et al. 2018. A role for Fc function in therapeutic monoclonal antibody-mediated
protection against ebola virus. Cell Host Microbe, 24,
221–233.
Hoffmann E,
Krauss S, Perez D, Webby R, Webster R G. 2002. Eight-plasmid system for rapid
generation of influenza virus vaccines. Vaccine, 20, 3165–3170.
Hu Z L, Hu S
L, Meng C C, Wang X Q, Zhu J, Liu X F. 2011. Generation of a genotype VII
Newcastle disease virus vaccine candidate with high yield in embryonated
chicken eggs. Avian Diseases, 55, 391–397.
Hu Z L, Liu X
F, Jiao X A. 2017. Newcastle disease virus (NDV) recombinant expressing the
hemagglutinin of H7N9 avian influenza virus protects chickens against NDV and
highly pathogenic avian influenza A (H7N9) virus challenges. Vaccine, 35,
6585–6590.
Hu Z L, Zhao
J Y, Shi L, Hu J, Hu S L, Liu X F. 2021. Identification of the dominant
non-neutralizing epitope in the haemagglutinin of H7N9 avian influenza virus. Virus Research, 298, 198409.
Hu Z L, Zhao
J Y, Zhao Y H, Fan X L, Hu J, Shi L, Wang X Q, Liu X W, Hu S L, Gu M, Cao Y Z,
Liu X F. 2019. Hemagglutinin-specific non-neutralizing antibody is essential
for protection provided by inactivated and viral-vectored H7N9 avian influenza
vaccines in chickens. Frontiers in Veterinary Science, 6, 482.
Ito M,
Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y. 2019.
Characterization of mouse monoclonal antibodies against the HA of A(H7N9)
influenza virus. Viruses, 11, 149.
Jackson L A,
Campbell J D, Frey S E, Edwards K M, Keitel W A, Kotloff K L, Berry A A, Graham
I, Atmar R L, Creech C B, Thomsen I P, Patel S M, Gutierrez A F, Anderson E L,
El Sahly H M, Hill H, Noah D L, Bellamy A R. 2015. Effect of varying doses of a
monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on
immune response: A randomized clinical trial. JAMA, 314, 237–246.
Kamal R P,
Blanchfield K, Belser J A, Music N, Tzeng W P, Holiday C, Burroughs A, Sun X,
Maines T R, Levine M Z, York I A. 2017. Inactivated H7 influenza virus vaccines
protect mice despite low levels of neutralizing antibodies. Journal of Virology, 91, e01202–e01219.
Krammer F.
2019. The human antibody response to influenza A virus infection and
vaccination. Nature Reviews. Immunology, 19,
383–397.
Lam A K,
Roshan R, Miley W, Labo N, Zhen J, Kurland A P, Cheng C, Huang H, Teng P L,
Harelson C, Gong D, Tam Y K, Radu C G, Epeldegui M, Johnson J R, Zhou Z H,
Whitby D, Wu T T. 2023. Immunization of mice with virus-like vesicles of Kaposi
Sarcoma-associated herpesvirus reveals a role for antibodies targeting ORF4 in
activating complement-mediated neutralization. Journal of Virology, 97, e0160022.
Li J X, Yang
Y, Wang M, Ren X H, Yang Z, Liu L Y, Zhang G Z, Chen Q, Yang W, Chen Y H, Wan X
C. 2019. Rapid isolation of a potent human antibody against H7N9 influenza
virus from an infected patient. Antiviral Research, 170,
104564.
Li M X, Chen
L, Wang Q G, Hao M C, Zhang X Q, Liu L L, Yu X, Yang C P, Xu J Q, Chen J J,
Gong R. 2019. A cross-reactive human monoclonal antibody targets the conserved
H7 antigenic site A from fifth wave H7N9-infected humans. Antiviral Research, 170, 104556.
Liu D, Zhang
Z J, He L H, Gao Z, Li J, Gu M, Hu J, Wang X Q, Liu X F. 2018. Characteristics
of the emerging chicken-origin highly pathogenic H7N9 viruses: A new threat to
public health and poultry industry. Journal of Infection, 76,
217–220.
Liu Q, Mena
I, Ma J, Bawa B, Krammer F, Lyoo Y S, Lang Y, Morozov I, Mahardika G N, Ma W,
Garcia-Sastre A, Richt J A. 2015. Newcastle disease virus-vectored H7 and H5
live vaccines protect chickens from challenge with H7N9 or H5N1 avian influenza
viruses. Journal of Virology, 89, 7401–7408.
Miller-Novak
L K, Das J, Musich T A, Demberg T, Weiner J A, Venzon D J, Mohanram V,
Vargas-Inchaustegui D A, Tuero I, Ackerman M E, Alter G, Robert-Guroff M. 2018.
Analysis of complement-mediated lysis of simian immunodeficiency virus (SIV)
and SIV-infected cells reveals sex differences in vaccine-induced immune
responses in rhesus macaques. Journal of Virology, 92,
e00721–e00739.
Nagy A, Lee
J, Mena I, Henningson J, Li Y, Ma J, Duff M, Lang Y, Yang J, Abdallah F, Richt
J, Ali A, Garcia-Sastre A, Ma W. 2016. Recombinant Newcastle disease virus
expressing H9 HA protects chickens against heterologous avian influenza H9N2
virus challenge. Vaccine, 34, 2537–2545.
Schmeisser F,
Vasudevan A, Verma S, Wang W, Alvarado E, Weiss C, Atukorale V, Meseda C, Weir
J P. 2015. Antibodies to antigenic site A of influenza H7 hemagglutinin provide
protection against H7N9 challenge. PLoS ONE, 10, e0117108.
Shi J Z, Deng
G H, Ma S J, Zeng X Y, Yin X, Li M, Zhang B, Cui P F, Chen Y, Yang H L, Wan X
P, Liu L L, Chen P C, Jiang Y P, Guan Y T, Liu J X, Gu W L, Han S Y, Song Y M,
Liang L B, et al. 2018. Rapid evolution of H7N9 highly pathogenic
viruses that emerged in China in 2017. Cell Host Microbe, 24,
558–568.
Shi L, Hu Z
L, Hu J, Liu D, He L H, Liu J, Gu H, Gan J J, Wang X Q, Liu X F. 2018. Single
immunization with Newcastle disease virus-vectored H7N9 vaccine confers a
complete protection against challenge with highly pathogenic avian influenza
H7N9 virus. Avian Diseases, 63, 61–67.
Sicca F,
Neppelenbroek S, Huckriede A. 2018. Effector mechanisms of influenza-specific
antibodies: Neutralization and beyond. Expert Review of Vaccines, 17, 785–795.
Stadlbauer D,
Rajabhathor A, Amanat F, Kaplan D, Masud A, Treanor J J, Izikson R, Cox M M,
Nachbagauer R, Krammer F. 2017. Vaccination with a recombinant H7
hemagglutinin-based influenza virus vaccine induces broadly reactive antibodies
in humans. mSphere, 2, e00502–e00519.
Sun S H, Zhao
G Y, Liu C F, Fan W, Zhou X J, Zeng L, Guo Y, Kou Z H, Yu H, Li J F, Wang R X,
Li Y, Schneider C, Habel M, Riedemann N C, Du L Y, Jiang S B, Guo R F, Zhou Y
S. 2015. Treatment with anti-C5a antibody improves the outcome of H7N9 virus
infection in African green monkeys. Clinical Infectious Diseases, 60, 586–595.
Tan G S, Leon
P E, Albrecht R A, Margine I, Hirsh A, Bahl J, Krammer F. 2016.
Broadly-reactive neutralizing and non-neutralizing antibodies directed against
the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathogens, 12, e1005578.
Wang X L,
Jiang H, Wu P, Uyeki T M, Feng L Z, Lai S J, Wang L L, Huo X, Xu K, Chen E F,
Wang X X, He J F, Kang M, Zhang R L, Zhang J, Wu J B, Hu S X, Zhang H J, Liu X
Q, Fu W J, et al. 2017. Epidemiology of avian influenza A H7N9
virus in human beings across five epidemics in mainland China, 2013–17: An
epidemiological study of laboratory-confirmed case series. Lancet Infectious Diseases, 17, 822–832.
Wibroe P P,
Helvig S Y, Moein Moghimi S. 2014. The role of complement in antibody therapy
for infectious diseases. Microbiology Spectrum, 2,
AID-0015–2014.
Yang F, Xiao
Y X, Lu R F, Chen B, Liu F M, Wang L Y, Yao H P, Wu N P, Wu H B. 2020.
Generation of neutralizing and non-neutralizing monoclonal antibodies against
H7N9 influenza virus. Emerging Microbes Infections, 9,
664–675.
Yin X, Deng G
H, Zeng X Y, Cui P F, Hou Y J, Liu Y J, Fang J Z, Pan S X, Wang D X, Chen X H,
Zhang Y P, Wang X R, Tian G B, Li Y B, Chen Y, Liu L L, Suzuki Y, Guan Y T, Li
C J, Shi J Z, et al. 2021. Genetic and biological properties of
H7N9 avian influenza viruses detected after application of the H7N9 poultry
vaccine in China. PLoS Pathogens, 17, e1009561.
Yu F, Song H,
Wu Y L, Chang S Y, Wang L L, Li W, Hong B B, Xia S, Wang C Y, Khurana S, Feng
Y, Wang Y P, Sun Z W, He B A, Hou D N, Manischewitz J, King L R, Song Y L, Min
J Y, Golding H, et al. 2017. A potent germline-like human
monoclonal antibody targets a pH-sensitive epitope on H7N9 influenza
hemagglutinin. Cell Host Microbe, 22, 471–483.
Zeng X Y, He
X W, Meng F, Ma Q, Wang Y, Bao H M, Liu Y J, Deng G H, Shi J Z, Li Y B, Tian G
B, Chen H L. 2022. Protective efficacy of an H5/H7 trivalent inactivated
vaccine (H5-Re13, H5-Re14, and H7-Re4 strains) in chickens, ducks, and geese
against newly detected H5N1, H5N6, H5N8, and H7N9 viruses. Journal of Integrative Agriculture, 21, 2086–2094.
|
